Candidature spontanée - Martigny
debiopharm
Martigny, Valais, Switzerland · Martigny · Switzerland
Posted May 28, 2026
- Other
debiopharm
Martigny, Valais, Switzerland · Martigny · Switzerland
Posted May 28, 2026
Debiopharm Group™ est un groupe biopharmaceutique international de cinq sociétés dont le siège social se trouve en Suisse, actif dans le monde entier dans les domaines du développement de médicaments, de la fabrication de médicaments exclusifs selon les BPF, des outils de diagnostics et de la gestion des investissements.
Debiopharm Research & Manufacturing SA est une société de recherche, développement et production pharmaceutique dotée d'installations conformes aux BPF et certifiées par les grandes autorités réglementaires. Centre d'expertise du groupe dans le domaine de la chimie thérapeutique, la société est numéro un mondial des produits injectables à base d'acide polylactique-coglycolique (PLGA).
Vous pouvez nous faire parvenir ici votre candidature spontannée pour la structure basée à Martigny.
Debiopharm is an independent biopharmaceutical company based in Switzerland with headquarters in Lausanne(VD) and a manufacturing site in Martigny (VS).We are committed to developing innovative therapies that target high unmet medical needs in oncology and infectious diseases with a broad range of expertise in drug development, drug manufacturing as well as investment in start-ups. Through our unique business model, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.Debiopharm is an independent biopharmaceutical company based in Switzerland with headquarters in Lausanne(VD) and a manufacturing site in Martigny (VS).
We are committed to developing innovative therapies that target high unmet medical needs in oncology and infectious diseases with a broad range of expertise in drug development, drug manufacturing as well as investment in start-ups.
Through our unique business model, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.